Mesalamine News
First and Only Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis Now Available in Canada
Shire plc, the global specialty biopharmaceutical company, today announced the availability in Canada of MEZAVANT(R)(*) (mesalamine delayed and extended release tablets) with Multi Matrix System (MMX(TM)(xx)) Technology,...
Survey Reveals Differing Physician, Patient Perceptions
Nearly three out of four patients with ulcerative colitis (UC) consider feeling unwell to be a normal part of life, while gastroenterologists estimate this to be true for only 37 percent of their UC patients, according to results...
FDA Approves Lialda First Once-daily Mesalamine for UC
FDA Approves LIALDA (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
Colitis patients need better immunization: report
People with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, are frequently not immunized against vaccine-preventable diseases, researchers report.
Oral Mesalamine Prodrug Approved for Active Ulcerative Colitis
Salix Pharmaceuticals has received approval to market balsalazide disodium (Colazal) oral capsules for treatment of mildly to moderately active ulcerative colitis. Salix expects to introduce Colazal in the first quarter of 2001.